There was no material change in the results after adjustment for age, gender, comorbidities (COPD and CHF), log vintage, inflammatory markers (albumin, NLR), hemoglobin and erythropoietin dose (HR 1.04 (1.01–1.08)) (Table 2). Here, EPO is linked to chronic obstructive pulmonary disease.